Abate As Industries Ltd

Agreement details

• Parties: Abate AS Industries Limited and Franchise India Brands Limited.
• Purpose: Franchise Development Program to expand ABATE Eye Hospital across India.
• Size/Consideration: INR 30,00,000 fixed fee.
• Term: 24 months from the effective date.
• Fees: Fixed consultancy and success-based fees linked to franchise acquisitions.
• Shareholding: NIL in counterparty.
• Related party: Not a related party transaction.
• Impact: Expansion of ABATE Eye Hospital via franchise model across India.
• Regulatory/Disclosures: SEBI LODR disclosure; no board changes disclosed.

Dematerialisation status

• Dematerialisation requests were confirmed to depositories, and securities listed on exchanges where earlier issues are listed.
• Certificates for dematerialisation were mutilated and cancelled after verification, with the depository recorded as owner within timelines.
• Detailed dematerialisation records for the period show NIL entries.
• No exceptions, delays, or non-compliance are noted in the certificate.

Abate As Industries Ltd trading window closed from Oct 1, 2026; reopens 48 hours after the unaudited results for the quarter/half year ended Sep 30, 2026 are announced

AGM Details

• AGM held on 16-09-2026 from 3:00 PM to 3:20 PM.
• Mode: conducted via video conferencing / OAVM.
• Record date: 09-09-2026.
• Last date for postal ballot receipt: 16-09-2026.
• Attendance via video conferencing: promoters 9, public 11.

Resolutions & Outcomes

• Ordinary: adoption of financial statements and auditor appointment — passed.
• Ordinary: re-appoint Jesh Puthussery by rotation — passed.
• Ordinary: re-appoint Abdul Nazar Jama as director — passed.
• Special: re-appoint Dr. [name redacted] as Executive Director without remuneration — passed.
• Ordinary: re-appoint Julie G Varghese as Independent Director for five years — passed.
• Ordinary: re-appoint Indu Kamala Ravindran as Independent Director for five years — passed.
• Special: Regularize appointment of non-executive independent director — passed.
• Special: Alteration of Object Clause of MOA — passed.

Directors & Appointments

• Re-appointment by rotation: Jesh Puthussery.
• Appointment of Abdul Nazar Jama as director (Independent).
• Executive Director appointment: Dr. [name redacted], without remuneration.
• Independent Directors: Julie G Varghese; Indu Kamala Ravindran.
• Non-executive independent director Regularization: name not disclosed.

MOA & Other Approvals

• Alteration of Object Clause of MOA.

Auditors

• Auditor appointment linked to Resolution 1; name not disclosed.

AGM Details

• Date, time, mode: 16 September 2026, 3:00 PM IST, via Video Conferencing.
• Meeting duration: 3:00–3:20 PM; 15-minute post-meeting e-voting window.
• Attendance: 20 members attended via VC.

Resolutions Proposed

• Ordinary: Adopt Audited Standalone and Consolidated Financial Statements for FY ended 31 March 2026.
• Ordinary: Appointment of Rajesh Puthussery as Director (retiring by rotation).
• Ordinary: Appointment of Abdul Nazar Jamal Kizhisseri as Director (retiring by rotation).
• Special: Re-appointment of Dr. Muhemmed Swadique as Executive Director for five years from Aug 14, 2026.
• Special: Re-appointment of Julie Varghese as Independent Director for a second five-year term from Aug 14, 2026.
• Special: Re-appointment of Indu Kamala Ravindran as Independent Director for a second five-year term from Dec 28, 2026.
• Special: Regularization of Aboobaker Vattamkandathil as Non-Executive Independent Director for up to five years from Aug 13, 2026.
• Special: Alteration of MOA Clause III(A)(1) to expand healthcare activities, digital health, and education.

Other Governance Details

• Auditors: Statutory and Secretarial auditors attended; no change indicated.
• Voting: Remote e-voting Sept 13-15, 2026 and AGM venue voting conducted; Scrutinizer appointed.
• Results: Final outcomes to be announced within two working days.

AGM Details

• Date and time: 16 September 2026 at 3:00 PM IST
• Mode: VC/OAVM
• Cut-off date for e-voting: 9 September 2026
• Book closure: 10 September 2026 to 16 September 2026
• Remote e-voting window: 13 September 2026 09:00 IST to 15 September 2026 17:00 IST

ordinary business

• Adopt standalone financial statements for FY 2025-26
• Adopt consolidated financial statements for FY 2025-26
• Appoint Rajesh Puthussery as Director (retiring by rotation)
• Appoint Abdul Nazar Jamal Kizhisseri Muhammed as Director (retiring by rotation)

Special business

• Re-appoint Dr Muhemmed Swadique as Executive Director for five years
• Re-appoint Ms Julie G Varghese as Independent Director for second term (Aug 2026–Aug 2031)
• Re-appoint Ms Indu Kamala Ravindran as Independent Director for second term (Dec 2026–Dec 2031)
• Regularize appointment of Aboobaker Vattamkandathil as Non-Executive Independent Director
• Alter MOA: expand main object to healthcare services

AGM & annual report access

• AGM scheduled for 16 September 2026 at 03:00 PM IST via VC/OAVM
• Annual Report for FY2025-26 and AGM Notice available on abateas.com; exact path /annual-report/
• Web-link provided for non-registered email holders per Benpos 14 August 2026

KYC & dematerialisation reminders

• Reminder to update KYC details and dematerialize physical securities per SEBI circular
• Forms ISR1-ISR3 and SH-13/SH-14 prescribed for updating nominations and KYC details

Governance note

• Company name: Abate AS Industries Limited (formerly Trijal Industries Limited)

AGM and book closure details

• AGM scheduled for 16 September 2026 at 03:00 PM IST via VC/OAVM.
• Book closure from 10 September 2026 to 16 September 2026 (inclusive) for AGM.
• Cut-off date for eligibility for remote e-voting and AGM voting: 9 September 2026.
• Remote e-voting opens 13 September 2026 at 09:00 IST and closes 15 September 2026 at 17:00 IST.

Financial performance

• Consolidated total income: ₹1,617.37 million; revenue from operations: ₹1,594.09 million.
• Standalone PAT: ₹1.54 crore; Consolidated PAT: ₹12.30 crore.
• Consolidated revenue growth vs 2024-25: substantial increase with international contribution.
• Earnings per share: ₹0.54 consolidated; ₹0.59 prior year.
• Intercompany eliminations: ₹10.30 million in consolidation.
• Dividend: not recommended for FY2025-26.

Capital structure & capital actions

• Bonus issue: 7,88,03,228 new shares; post-bonus paid-up capital ₹157.60 crore.
• Authorized capital increased to ₹158 crore (Phase I) and ₹200 crore (Phase II).
• Share swap via preferential allotment: 7,37,87,128 shares issued on Feb 25, 2025.
• Shareholding after swap: Promoter group 27.56%; Public 72.44%.

Business development & strategy

• Plan to build a global network of 44 eye hospitals.
• New Manjeri superspecialty eye hospital planned; Bahrain expansion underway.
• MOA object clause expanded to healthcare infra and digital health.
• Education plans include a private healthcare university; strategic partnerships contemplated.
• Expansion includes international patient services and medical tourism.

Operations & segment performance

• Sky International Trading WLL contributed ₹1,234.50 million revenue.
• Prudential Management Services: ₹309.50 million revenue.
• Salamath Import & Exports: ₹60.38 million revenue.
• Group procedures: 9,147; Perinthalmanna center ~73% of procedures.
• Cataract surgeries 55%; retina injections 32%; retina surgeries 8%.

Governance & controls

• Board comprises 16 directors; 8 Independent; women directors on board.
• Ambramoli Purushothaman resigned 27 Nov 2025; Harikumar added 12 Feb 2026.
• Independent Directors met 12 Feb 2026; disclosures and familiarisation documented.
• SOP fines paid to BSE for 2024-25; no material non-compliance reported.
• Secretarial audit: no qualifications; governance policies published on website.

Subsidiaries & associate

• Subsidiaries: Salamath Import & Exports Private Limited, Prudential Management Services Private Limited, Sky International Trading WLL.
• Associate: SAIA Educational Support Services WLL.
• Consolidation includes 3 subsidiaries and 1 associate; intercompany eliminations ₹10.30 million.
• Cross-border Bahrain operations with international strategic significance.

Audit & disclosures

• Statutory Auditor: Mahesh C Solanki & Co; Secretarial Auditor: Lakshmmi Subramanian & Associates.
• Secretarial audits for Salamath and Prudential: unqualified.
• Form MGT-9 not filed; annual return hosted on company website.
• Related party transactions are at arm's length; detailed in AOC-2.

Outlook & risks

• Opportunities: telemedicine, digital health, acquisitions, and medical tourism.
• Risks: regulatory changes, talent retention, cybersecurity, inflation, competition.
• Management focus on governance, capital discipline, and stakeholder value.